17th World ADC San Diego Leaderboard
  • Friday, May 15, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Obesity & Weight Loss Drug Development Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 358

Author

Pharma Journalist 8791 posts 0 comments

HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline With Two Lead…

Jun 15, 2021
HiFiBiO Therapeutics, a multinational biotechnology company with unique expertise in immune modulation and drug intelligent science, announced the completion of an oversubscribed $75M…
Read More...

Moderna and Tabuk Pharmaceuticals Partner to Commercialize Moderna’s COVID-19 Vaccine in Saudi…

Jun 14, 2021
Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra…
Read More...

FDA Takes Steps to Increase Availability of COVID-19 Vaccine

Jun 14, 2021
Following careful review and deliberation, the U.S. Food and Drug Administration is taking important steps that will allow a critically needed supply of the Janssen (Johnson &…
Read More...

Vicore announces FDA acceptance for pivotal phase 3 trial of C21 in COVID-19

Jun 11, 2021
Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as idiopathic pulmonary fibrosis…
Read More...

Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl…

Jun 11, 2021
Bristol Myers Squibb and Acceleron Pharma Inc. announced the first data from the Phase 2 BEYOND study evaluating Reblozyl(luspatercept-aamt), a first-in-class erythroid maturation…
Read More...

Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation…

Jun 11, 2021
Pfizer Inc. and BioNTech SE announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies’ COVID-19 vaccine, 200 million doses in 2021 and…
Read More...

Avantor Completes Acquisition of Ritter GmbH and its Affiliates

Jun 10, 2021
Avantor, Inc. a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, announced it…
Read More...

Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral…

Jun 10, 2021
Merck, known as MSD outside the United States and Canada, today announced it has entered into a procurement agreement with the United States government for molnupiravir (MK-4482).…
Read More...

Exclusive Interview – Neuropathic Pain Therapeutics Digital Summit

Jun 10, 2021

Read More...

Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of…

Jun 9, 2021
Arena Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to etrasimod, a highly selective, once-daily, oral…
Read More...
Prev Next
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
5th World ADC Summit South Korea
Extrahepatic Lipid-Based Nanoparticles Delivery Summit
World TPD & Induced Proximity Summit South Korea
Investigative & Preclinical Toxicology Summit 2026
LEAP HR: Life Sciences West
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
R&D Procurement & Sourcing in Pharma Summit
In Vivo Cell Engineering & Gene Editing Summit
PFS & Injectable Drug Delivery West Coast
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
World Bispecific & T-Cell Engager Summit South Korea
TCR-Based Therapies Summit
Nasal Formulation & Delivery Summit
ALS Drug Development Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • World ADC San Diego Unveils Preliminary Agenda for 17th Annual Meeting
  • GSK Partners With Sino Biopharmaceutical on Hepatitis B Drug
  • EU Approves Sotyktu for Psoriatic Arthritis
  • FDA Seeks Public Input on Drug Repurposing Efforts
  • FDA Approves BIZENGRI for NRG1+ Cholangiocarcinoma

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

Turning Biophysical Data into Confident Drug Discovery…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.